| 000 | 01145 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250516081455.0 | ||
| 264 | 0 | _c20120612 | |
| 008 | 201206s 0 0 eng d | ||
| 022 | _a1756-1833 | ||
| 024 | 7 |
_a10.1136/bmj.e1451 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _ade Oliveira, Jose Mario Franco | |
| 245 | 0 | 0 |
_aUtility of GLP-1R agonists in diabetes requires long term study. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cFeb 2012 |
||
| 300 |
_ae1451; author reply e1459 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 |
_aAnti-Obesity Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide 1 _xanalogs & derivatives |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aOverweight _xdrug therapy |
| 650 | 0 | 4 |
_aPeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Glucagon _xagonists |
| 650 | 0 | 4 |
_aVenoms _xtherapeutic use |
| 650 | 0 | 4 |
_aWeight Loss _xdrug effects |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 344 _gp. e1451; author reply e1459 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.e1451 _zAvailable from publisher's website |
| 999 |
_c21583401 _d21583401 |
||